The Alliance for Clinical Research Excellence and Safety (ACRES) announced the launch of ACRES BlueCloud™
The Alliance for Clinical Research Excellence and Safety (ACRES) announced the launch of ACRES BlueCloud™, the first phase implementation of a shared multi-user interface to allow sponsors, CROs, regulatory agencies, funding agencies and IRBs to access verifiable professional experience and training credentials, for sharing and mutual recognition credentials by multiple stakeholders.
The technology also provides a global integration platform through which stakeholders can access and deploy already established technology solutions and collaborative data warehouses to support a global system for high-performance Accountable Research™. ACRES’ strategic ally HealthCarePoint, a Texas-based healthcare and clinical research networking-technology corporation, provides the ACRES BlueCloud™capabilities. HealthCarePoint is among several technology companies and standards organizations comprising ACRES’ global Technology Consortium. Rollout of the ACRES Blue Cloud™ platform will begin immediately by providing the technology free of charge to clinical research sites worldwide, thereby extending and leveraging the existing global network of nearly three-quarter million current BlueCloud™ users from some 60,000 healthcare and research-related organizations worldwide. The network’s single sign-on interface will allow sites to connect with sponsors, CROs, ethics committees (IRBs) and other stakeholders through a unified platform, sharing critical professional and operational information, such as GCP training certifications and other professional credentials. As other provider technologies integrate with the shared platform through application programming interfaces, commonly known as APIs, additional functionality will be added.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
2 Commerce Drive
Cranbury, NJ 08512